Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong <i>in vivo</i> Antitumor Activity-Reference-Cited by-同舟云学术

Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong in vivo Antitumor Activity

Published:2023-07-31 Issue:15 Volume:66 Page:10761-10781
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Yang Lin¹,Tu Wenbin¹²,Huang Liyue²,Miao Bukeyan²,Kaneshige Atsunori¹²,Jiang Wei²³,Leng Lingying²,Wang Meilin⁴,Wen Bo⁴,Sun Duxin³⁴^ORCID,Wang Shaomeng¹²⁵³^ORCID

Affiliation:

1. Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States

2. Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States

3. Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, United States

4. Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States

5. Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109, United States

Funder

National Cancer Institute

Proteovant Therapeutics Inc.

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c00953

Reference47 articles.

1. Marked for death: targeting epigenetic changes in cancer

2. Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics

3. The Spectrum of SWI/SNF Mutations, Ubiquitous in Human Cancers

4. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary

5. Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glutathione-dependent degradation of SMARCA2/4 for targeted lung cancer therapy with improved selectivity;European Journal of Medicinal Chemistry;2024-11

2. Recent contributions of pyridazine as a privileged scaffold of anticancer agents in medicinal chemistry: An updated review;Bioorganic & Medicinal Chemistry;2024-09

3. Stereochemical inversion at a 1,4-cyclohexyl PROTAC linker fine-tunes conformation and binding affinity;Bioorganic & Medicinal Chemistry Letters;2024-09

4. Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C Inhibitors;2024-08-26

5. Chromatin remodellers as therapeutic targets;Nature Reviews Drug Discovery;2024-07-16